Literature DB >> 16439680

Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.

Raymond L Comenzo1, Ping Zhou, Martin Fleisher, Bradly Clark, Julie Teruya-Feldstein.   

Abstract

Investigators in the United Kingdom have shown that hereditary amyloidosis can be misdiagnosed as Ig light-chain (AL) amyloidosis because family history is an ineffective screen, and tissue staining used to type amyloid is unreliable. Misdiagnosis of AL can lead to inappropriate use of chemotherapy and failure to diagnose a hereditary disease. Over a 3-year period we sought to determine how often both possible sources of amyloidosis occurred in the same patient. We employed an algorithm based on established data and patterns of amyloidosis in order to focus the screening effort. Of 178 consecutive patients referred for amyloidosis, 54 were screened by polymerase chain reaction techniques with primers designed to detect transthyretin, apolipoprotein AI, apolipoprotein AII, fibrinogen Aalpha, and lysozyme variants. Three patients (6% of those screened and 2% of symptomatic patients) had both a monoclonal gammopathy and a hereditary variant. These results justify further study of screening for hereditary variants in patients with apparent AL, and highlight the need for practical techniques for identifying fibrils extracted from tissue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439680     DOI: 10.1182/blood-2005-10-4148

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Systemic amyloidosis: a challenge for the rheumatologist.

Authors:  Federico Perfetto; Alberto Moggi-Pignone; Riccardo Livi; Alessio Tempestini; Franco Bergesio; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

2.  Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego).

Authors:  Angela Dispenzieri; Giampaolo Merlini; Raymond L Comenzo
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

3.  Sporadic transthyretin amyloidosis with a novel TTR gene mutation misdiagnosed as primary amyloidosis.

Authors:  Chiara Briani; Tiziana Cavallaro; Sergio Ferrari; Federica Taioli; Sara Calamelli; Laura Verga; Fausto Adami; Gian Maria Fabrizi
Journal:  J Neurol       Date:  2012-05-12       Impact factor: 4.849

Review 4.  New insights and modern treatment of AL amyloidosis.

Authors:  Chakra P Chaulagain; Raymond L Comenzo
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 5.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

6.  Direct tissue evaluation via immunofluorescence: in the diagnosis of hereditary transthyretin cardiac amyloidosis.

Authors:  Michael G Fradley; Joseph V Thakuria; A Bernard Collins; Stephanie A Moore; James R Stone
Journal:  Tex Heart Inst J       Date:  2012

7.  Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series.

Authors:  Charles L Murphy; Shuching Wang; Daniel Kestler; Christopher Larsen; Don Benson; Deborah T Weiss; Alan Solomon
Journal:  Am J Kidney Dis       Date:  2010-10-16       Impact factor: 8.860

8.  The amyloidoses: clinical features, diagnosis and treatment.

Authors:  Kelty R Baker; Lawrence Rice
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

9.  Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.

Authors:  Maike F Dohrn; Christoph Röcken; Jan L De Bleecker; Jean-Jacques Martin; Matthias Vorgerd; Peter Y Van den Bergh; Andreas Ferbert; Katrin Hinderhofer; J Michael Schröder; Joachim Weis; Jörg B Schulz; Kristl G Claeys
Journal:  J Neurol       Date:  2013-10-08       Impact factor: 4.849

Review 10.  [Current diagnostic and therapy of light chain amyloidosis].

Authors:  S O Schönland; T Bochtler; A V Kristen; A D Ho; U Hegenbart
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.